Physician profile
Mohammad A Hammoude
NPI 1265559488
$18,170.80
in general payments reported to CMS, 2019-2025
56 companies · $3,816 in 2025
The $3,816 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,809 · 2020: $1,035 · 2021: $2,484 · 2022: $2,620 · 2023: $3,102 · 2024: $3,305 · 2025: $3,816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $65.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,156.49 |
| Education | $65.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,397.08 | 2020-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $2,394.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $1,476.98 | 2019-2025 | |
| Lilly USA, LLC | $1,435.51 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,432.95 | 2019-2025 | Tepezza, Evenity, Prolia |
| Dexcom, INC. | $949.39 | 2019-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Corcept Therapeutics | $933.52 | 2019-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $844.59 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $720.58 | 2020-2025 | Jardiance, Tradjenta, Synjardy |
| Amneal Pharmaceuticals LLC | $621.78 | 2020-2025 | Unithroid |
| Xeris Pharmaceuticals, INC. | $403.47 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Horizon Therapeutics Plc | $375.48 | 2022-2023 | Tepezza |
| Abbvie INC. | $360.17 | 2021-2025 | |
| Medtronic Minimed, INC. | $279.49 | 2019-2020 | |
| Mannkind Corporation | $273.95 | 2019-2025 |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $248.75 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $226.29 | 2019-2021 | |
| Cequr Corporation | $198.47 | 2022-2025 | Cequr Simplicity |
| Ascendis Pharma Endocrinology INC | $197.32 | 2025 | Yorvipath |
| Insulet Corporation | $196.58 | 2021-2025 | Omnipod |
| Boston Scientific Corporation | $191.74 | 2022-2024 | Wavewriter Alpha Prime 16 |
| Sequel Med Tech, LLC | $168.57 | 2025 | Twiist |
| Becton, Dickinson and Company | $166.88 | 2019-2022 | |
| Amarin Pharma, INC. | $152.75 | 2020-2022 | |
| Antares Pharma, INC. | $152.74 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Recordati_rare_diseases_inc. | $151.62 | 2022-2025 | Isturisa, Signifor Lar |
| Medtronic, INC. | $102.36 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Alexion Pharmaceuticals, INC. | $94.58 | 2023-2025 | Strensiq |
| Nevro Corp. | $93.78 | 2023-2024 | Senza |
| Beta Bionics, INC. | $80.36 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Eusa Pharma (US) LLC | $68.75 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $66.45 | 2019-2024 | Crysvita |
| Alvogen INC | $64.33 | 2022-2023 | Teriparatide |
| Madrigal Pharmaceuticals | $58.96 | 2025 | Rezdiffra |
| Tandem Diabetes Care, INC. | $53.72 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Tolmar, INC. | $49.35 | 2024-2025 | Jatenzo |
| Shire North American Group INC | $44.35 | 2019 | |
| Radius Health, INC. | $41.89 | 2022-2024 | Tymlos |
| Janssen Pharmaceuticals, INC | $41.39 | 2019-2020 | |
| Amryt Pharma Holdings LTD | $38.67 | 2022-2023 | Mycapssa |
| Embecta Corp. | $38.32 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Astellas Pharma US INC | $33.12 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.21 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.98 | 2020 | |
| Sanofi Pasteur INC. | $20.92 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $20.67 | 2025 | |
| Kyowa Kirin, INC. | $20.24 | 2025 | |
| Neurocrine Biosciences, INC. | $19.42 | 2024 | |
| Theracosbio, LLC | $19.25 | 2024 | Brenzavvy |
| Ibsa Pharma INC. | $17.09 | 2025 | Tirosint, Flector, Licart |
| Evoke Pharma, INC. | $16.75 | 2025 | |
| Halozyme INC | $14.65 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $14.17 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $13.92 | 2019 | |
| Pfizer INC. | $13.44 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $12.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Hammoude listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.